CONMED Corporation

NYSE:CNMD

Medical - Devices

Healthcare
$48.01 +0.75%

+$0.24 today

Market cap
$1.43B
Beta
0.92
P/E (TTM)
18.0
EPS (TTM)
$1.79
Dividend yield
1.24%
52W Low $31.84High $56.64

Volume 0.36M

Average 0.45M

CNMD Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

CONMED CorporationNYSE: CNMD

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures dips below year-ago levels

Q1 FY2026 capital expenditures of $2.89M (cash outflow) fell 23.5% year over year, behind the +27.6% change in trailing-twelve-month capital expenditures. Sequentially, it fell 43.4% from the prior quarter. Over 3 fiscal years it compounded at -3.1% a year.

Context

  • Capital expenditures amounted to 1.4% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -23.5% toward the trailing-twelve-month pace of +27.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.89M-43.4% QoQ
Last fiscal yearDec 2025
-$19.81M+51.4% YoY
LTMMar 2026
-$18.92M+27.6% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.5%——
1 year+51.4%——
3-year CAGR-3.1%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(19.81M) USD
Year-over-year change
-51.4%

Capital Expenditures vs competitors

How CNMD compares with its peers on the latest reported figures

  • CNMD's LTM Mar 2026 capital expenditures of $18.92M is the 6th largest of the 11 companies compared; the peer median is $15.67M.
  • Its year-over-year change of +27.6% is the 6th highest of 11, against a peer median of +11.9%.
  • Capital expenditures amounts to 1.4% of revenue for CNMD, versus a peer median of 3.6%.
CNMD Competitors Peer median
Capital Expenditures for CNMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AHCOAdaptHealth Corp.LTM Apr 2026$408.02M +30.0%-0.8%14.3%
NEOGNeogen CorporationLTM Aug 2026$35.5M -60.6%-7.9%4.0%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$33.27M +68.5%—39.7%
AZTAAzenta, Inc.LTM Sep 2026$30.08M -11.2%-8.6%4.8%
NVCRNovoCure LimitedLTM Mar 2026$21.19M -49.2%+7.7%3.1%
CNMDCONMED CorporationLTM Mar 2026$18.92M +27.6%-3.1%1.4%
UFPTUFP Technologies, Inc.LTM Jun 2026$10.16M -6.2%-2.1%1.6%
ESTAEstablishment Labs Holdings Inc.LTM Sep 2026$8.27M +35.5%-41.9%3.1%
SSIISS Innovations International, Inc.LTM Mar 2026$2.84M +101.9%—5.9%
INMDInMode Ltd.LTM Mar 2026$1.12M +73.4%-14.9%0.3%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$473K -88.2%-53.7%0.7%
Peer median (excluding CNMD) $15.67M+11.9%-8.3%3.6%

Competitors are the stored peer set for CNMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income62.54M(80.58M)64.46M132.42M47.06M
Depreciation & Amortization70.74M69.52M51.4M51.31M74.28M
Deferred Income Tax3.01M(6.04M)700K12.2M3.52M
Stock-Based Compensation16.34M21.73M24.26M25.56M28.32M
Change in Working Capital(55.7M)(90.7M)(39.58M)(39.72M)(11.45M)
Accounts Receivables(9.16M)(5.2M)(47.07M)(1.62M)(2.36M)
Inventory(37.81M)(78.56M)14.07M(31.63M)(6.73M)
Accounts Payables4.89M13.3M14.85M14.71M(9.75M)
Other Working Capital(13.62M)(20.23M)(21.43M)(21.19M)7.39M
Other Non-Cash Items14.84M119.44M24.11M(14.8M)28.96M
Operating Cash Flow111.77M33.37M125.35M166.97M170.69M
Capital Expenditures(14.87M)(21.79M)(19.03M)(13.08M)(19.81M)
Acquisitions (Net)0(227.74M)000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(1M)0(1.15M)
Investing Cash Flow(14.87M)(249.53M)(20.03M)(13.08M)(20.96M)
Debt Repayment(81.24M)362.02M(88M)(72M)(74.59M)
Common Stock Issued072M000
Common Stock Repurchased0(72M)000
Dividends Paid(23.26M)(23.96M)(24.5M)(24.65M)(24.75M)
Other Financing Activities2.95M(113.06M)2.07M(54.35M)(36.49M)
Financing Cash Flow(101.55M)225M(110.43M)(151M)(135.82M)
Effect of Forex Changes(1.87M)(741K)470K(2.72M)2.45M
Net Change in Cash(6.51M)8.1M(4.65M)163K16.36M
Free Cash Flow96.9M11.58M106.32M153.88M150.88M

CONMED Corporation

NYSE:CNMD

Intrinsic Alpha fair value

Locked

Current Price

$48.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.